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Abstract
Background: Lung cancer is one of the leading causes of cancer death worldwide. Non-small-cell lung cancer (NSCLC)
accounts for approximately 85% of all lung cancers. Immunotherapy has yielded no consistent benefit to date for those
patients. Assessing the objective efficacy and safety of immunotherapy for advanced NSCLC patients will help to instruct the
future development of immunotherapeutic drugs.
Methodology and Principal Findings: We performed a meta-analysis of 12 randomized controlled trials including 3134
patients (1570 patients in the immunotherapy group and 1564 patients in the control group) with histologically confirmed
stage IIIA, IIIB, or IV NSCLC. The analysis was executed with efficacy end points regarding overall survival (OS), progression-
free survival (PFS), complete response (CR), partial response (PR), and total effective rate. Overall unstratified OS, PFS, PR, and
total effective rate were significantly improved in advanced NSCLC patients in the immunotherapy group (P=0.0007,
0.0004, 0.002, 0.003, respectively), whereas CR was not improved (P=0.97). Subgroup analysis showed that monoclonal
antibody (mAb) immunotherapy significantly improved the PFS, PR, and total effective rate and showed a trend of
improving OS of advanced NSCLC patients compared with the control group, with one kind of adverse event being
significantly dominant. Compared with the control group, the vaccine subgroup showed no significant difference with
regard to serious adverse events, whereas cytokine immunotherapy significantly induced three kinds of serious adverse
events.
Conclusions: Immunotherapy works efficiently on advanced NSCLC patients. Of several immunotherapies, mAb therapy
may be a potential immunotherapy for advanced NSCLC patients, and become a standard complementary therapeutic
approach in the future if the issues concerning toxicity and allergenicity of mAbs have been overcome.
Citation: Wang J, Zou Z-H, Xia H-L, He J-X, Zhong N-S, et al. (2012) Strengths and Weaknesses of Immunotherapy for Advanced Non-Small-Cell Lung Cancer: A
Meta-Analysis of 12 Randomized Controlled Trials. PLoS ONE 7(3): e32695. doi:10.1371/journal.pone.0032695
Editor: Chiyu Zhang, Jiangsu University, China
Received September 21, 2011; Accepted January 30, 2012; Published March 5, 2012
Copyright:  2012 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Key Program from Guangdong Provincial Natural Science Foundation (8251018201000002) and Programs from National
Natural Science Foundation of China (No.30640033, No.30771240). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: taoailin@gzhmc.edu.cn
Introduction
In 2008, lung cancer was the most commonly diagnosed cancer,
as well as the leading cause of cancer death in males worldwide.
Among females, it was the fourth most commonly diagnosed
cancer and the second leading cause of cancer death [1]. Non-
small-cell lung cancer (NSCLC) accounts for approximately 85%
of all lung cancers [2].
Despite recent advances in surgery, irradiation, and chemo-
therapy, the prognosis of patients with lung cancer is still poor [3].
About 50% of patients recur after surgery, and less than 25% of
patients respond to systemic chemotherapy [4]. For patients with
unresectable stage III NSCL, chemotherapy has limited benefits
[5,6]. For advanced NSCLC patients, chemotherapy induces
significant safety issues. For example, in one study including 1371
patients, of 58% patients who received chemotherapy, 35% had
adverse events (AEs) and more than 12% had serious AEs [7].
Thus, it urgently requires safer and more effective treatments for
lung cancer to improve the quality and duration of life.
Immunotherapy seems an attractive therapeutic approach for lung
cancer due to its theoretical specificity and potential for long-term
disease control [8]. At present, the main strategies of immunother-
apy for advanced NSCLC include vaccines, cytokines, and
monoclonal antibodies (mAbs). Vaccine immunotherapy prompts
the immune system to kill cancer cells [9], immunotherapy with
cytokines counteracts the immunodeficiency state caused by the
tumor, and monoclonal antibodies (mAbs) target specific tumor
antigens and induce immune response against cancer [10].
However, immunotherapy trials for lung cancer have yielded no
consistent benefit to date in humans because tumor cells can escape
the immune attackand develop differentresistance mechanisms [9].
Combination of immunotherapy with surgery, chemotherapy, or
radiotherapy may be valuable in NSCLC patients; nevertheless the
model of multi-modality in NSCLC is still being debated.
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provides an avenue for evaluating the efficacy and side effects of
immunotherapy for advanced NSCLC patients. In this study, we
used a meta-analysis to evaluate the efficacy and safety of the
immunotherapies (including chemo-immunotherapy) on advanced
NSCLC patients.
Methods
Literature Search Strategy
This meta-analysis adhered to the relevant criteria of the
PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) statement [11]. A search was conducted on
Highwire (PubMed included) for original studies published
between January 1980 and April 2011 on immunotherapy for
NSCLC, using the following keywords: ‘‘immunotherapy’’ OR
‘‘immunotherapeutic’’ AND ‘‘non-small-cell lung cancer’’ OR
‘‘NSCLC.’’ Review papers were also examined for published
results. By carefully examining the body of each publication and
the names of all authors, we avoided duplications of data. When
such duplications were identified, the latest version was included in
this study. The search strategy used is illustrated in Figure 1.
Selection Criteria
The selection criteria were as follows: (1) studies were in the
English language and were limited to human trials; (2) data
regarding tumors without specific documentation of lung origin
were excluded; (3) case studies, review articles, and studies
involving fewer than three patients were excluded; and (4) studies
adopting randomized controlled trials to compare immunotherapy
versus control therapy and including patients at stage IIIA, IIIB, or
IV were included.
Data Extraction and Quality Assessment
Three reviewers, JW, HLX and ALT, independently selected
the trials and performed the data extraction. Discrepancies were
resolved by discussion among the reviewers. The clinical outcomes
used to evaluate efficacy and safety of immunotherapy in
advanced NSCLC were overall survival (OS), progression-free
survival (PFS), complete response (CR), partial response (PR), and
the total effective rate (CR + PR). OS was defined as the period
from the randomization date to the date of death. PFS was defined
as the period from the randomization date to the date when
disease progression (or death) was observed. We assessed the
objective cancer response as total effective rate, CR, and PR.
For the meta-analysis of immunotherapy for NSCLC, the
overall quality of each study was assessed in accordance with the
Jadad Scale [12]. A grading scheme (a, b, and c) was used to
classify four main criteria: (1) quality of randomization; (2) quality
of allocation concealment; (3) quality of blinding; and (4) quality of
the description of withdrawals and dropouts [13]. The grades
indicate: (a) adequate, with appropriate procedures; (b) unclear,
inappropriate description of methods; and (c) inadequate proce-
dures, methods, or information [14]. Based on these four criteria,
each study cited can be categorized as follows: A. studies have a
low risk of bias and were scored as grade a for all items; B. studies
have a moderate risk of bias with one or more grades of b; and C.
studies have a high risk of bias with one or more grades of c.
Assessment of Safety
For the trials included in this study, different grades of toxicity
and serious adverse events (SAEs) were observed during the
follow-up periods. An event that was fatal, life-threatening,
required hospitalization or prolonged existing hospitalization, or
caused a persistent or significant disability/incapacity was defined
as an SAE [15]. AEs were graded using the National Cancer
Institute Common Toxicity Criteria, version 2.0, except AEs
reported by Lissoni et al. [16], which were graded using WHO
criteria.
The included trials were classified into three subgroups
(cytokines, mAbs, and vaccines) based on the three categories of
immunotherapeutic drugs administered for advanced NSCLC.
Subgroup analysis of the SAEs was performed using Peto odds
ratio [17] to assess the significance of differences between the
experimental arm and its control arm in each subgroup.
Statistical Analysis
Statistical analysis was carried out using Review Manager
(version 5.0) provided by The Cochrane Collaboration. Dichot-
omous data are presented as hazard ratios (HR) and continuous
outcomes as weighted mean differences, both with the 95%
confidence interval (CI). HR and CI were calculated according to
Cox proportional hazards modeling [18]. An HR,1 means a
lower rate of events in the maintenance arm [19]. The overall
effect was tested using Z scores, with significance set at P,0.05.
Meta-analysis was performed using random-effect or fixed-effect
methods, depending on the presence or absence of significant
heterogeneity [20]. Statistical heterogeneity between trials was
evaluated by the x
2 and I
2 tests, with significance set at P,0.10.
When heterogeneity was confirmed, the random-effect method
was used. In the absence of statistically significant heterogeneity,
the fixed-effect method was used to combine the results. Sensitivity
analysis was conducted with alternative exclusion of trials by
Neninger Vinageras et al. [21] or Butts et al. [22], two trials that
did not apply chemotherapy in both the experimental and control
arms.
Figure 1. Study Flowchart.
doi:10.1371/journal.pone.0032695.g001
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Author [Reference]
Randomization
(grades)
Allocation concealment
(grades)
Blinding
(grades)
Description of
withdrawals (grades) Category
Lissoni et al. [16] a a a a A
Neninger Vinageras et al. [21] a a a a A
Butts et al. [22] a a a a A
Gatzemeier et al. [23] a a a a A
Lasalvia-Prisco et al. [24] a a a a A
Lynch et al. [25] a a a a A
O’Brien et al. [26] a a a a A
Pirker et al. [27] a a a a A
Ridolfi et al. [28] a a a a A
Rosell et al. [29] a a a a A
Wu et al. [30] a a a a A
Zhong et al. [31] a a a a A
a: adequate, with correct procedures;
b: unclear, without a description of methods; and.
c: inadequate procedures, methods, or information. A studies have a low risk of bias and were scored as grade a for all items.
doi:10.1371/journal.pone.0032695.t002
Figure 2. Forest plot of comparison of overall survival of 11 included studies (Stage IIIA, IIIB, or IV NSCLC). P values are from P-for-
effect modification testing for heterogeneity within or across the groups of regimens. The sizes of data markers are proportional to the number of
deaths in the trials. CI, confidence interval; HR, hazard ratio.
doi:10.1371/journal.pone.0032695.g002
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Quantity of Evidence
A total of 287 studies were identified by the searches. By
scanning titles and abstracts, redundant publications, reviews,
meeting abstracts, and case reports were excluded. After referring
to full texts, we removed 275 studies that did not meet the selection
criteria (Figure 1). As a result, 12 studies [16,21–31] that included
a total of 3134 patients were selected for meta-analysis.
The details of the 12 trials are listed in Table 1. Although six
studies did not describe OS [23] or PFS [16,21,22,24,26] and four
studies did not provide the number of patients in CR and/or PR
rates [22,26,29,31], all 12 studies were open-labeled and
randomized. They mentioned the concealment of allocation
clearly in the randomization process, and provided the number
of patients who withdrew from the trials. Therefore, the 12 studies
provided adequate information and were thus considered to be A.
studies in this meta-analysis (Table 2).
Meta-Analysis of Immunotherapy for Advanced NSCLC
The analysis results of OS are shown in Figure 2. No significant
heterogeneity was detected for total unstratified immunotherapy
or the three subgroups defined by immunotherapeutic categories
(Figure 2). A fixed-effect model was therefore used for OS analysis.
The overall analysis showed that immunotherapy significantly
increased OS at the end of follow-up compared with the control
group (Z=3.39, P=0.0007). However, subgroup patients did not
consistently gain an OS benefit from the various immunothera-
pies. The vaccine group behaved the same as total unstratified
immunotherapy and improved OS significantly (HR=0.94, 95%
CI=0.89–0.98; Z=2.59, P=0.009), whereas the cytokine group
(HR=0.92; 95% CI=0.83–1.01; Z=1.75, P=0.08) and mAb
group (HR=0.96, 95% CI=0.93–1.00; Z=1.96, P=0.05) did
not produce any significant improvement in OS compared with
their corresponding control groups.
Because the vaccine trials did not present PFS data, only the
mAb and cytokine groups were subjected to subgroup analysis. No
obvious heterogeneity (x
2=8.78, df=6, P=0.19; I
2=32%, 95%
CI=0–71%) was detected for total unstratified immunotherapy
(Figure 3). Heterogeneity was observed in both the mAb and
cytokine groups, allowing the use of different models for the overall
and subgroup analyses of PFS. mAbs clearly delayed the time to
disease progression (HR=1.09, 95% CI=1.04–1.15; Z=3.75,
P=0.0002), which was consistent with overall immunotherapy
(HR=1.08, 95% CI=1.03–1.12; Z=3.51, P=0.0004). However,
compared with the control group, patients in cytokines group did
not have a significant improvement in PFS (HR=0.99, 95%
CI=0.92–1.07; Z=0.24, P=0.81).
Because of no heterogeneity, fixed-effect models were used to
analyze total effective rates and PR rates of total unstratified
immunotherapy group and all subgroups (Figures 4 and 5). The
overall analysis demonstrated that immunotherapy substantially
improved both the total effective rate (HR=1.19, 95% CI=1.06–
1.34; Z=3.01, P=0.003) and PR rate (HR=1.23, 95%
CI=1.08–1.40, Z=3.07, P=0.002) compared with the control
arms. mAb therapy significantly improved the total effective rate
(HR=1.27, 95% CI=1.11–1.46, Z=3.42, P=0.0006) and PR
rate (HR=1.27, 95% CI=1.10–1.46, Z=3.32, P=0.001),
whereas cytokine and vaccine immunotherapy both generated
no statistically significant improvement.
Figure 3. Forest plot of comparison of progression-free survival of 7 included studies (Stage IIIA, IIIB, or IV NSCLC). P values are from
P-for-effect modification testing for heterogeneity within or across the groups of regimens. The sizes of data markers are proportional to the number
of PFS events in the trials. CI, confidence interval; HR, hazard ratio.
doi:10.1371/journal.pone.0032695.g003
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the overall immunotherapy group and three subgroups. The
results showed that neither total unstratified immunotherapy
(HR=1.00, 95% CI=0.77–1.31; Z=0.03, P=0.97) nor the
immunotherapy subgroups had a significant impact on CR rate
compared with their corresponding control arms (Figure 6).
Because not all the efficacy parameters were reported by all the
trials reviewed, sensitivity analyses were performed separately on
each parameter following the alternative exclusion of the trials by
Neninger Vinageras et al. [20] or Butts et al. [21], which did not
apply chemotherapy. For the efficacy parameters analyzed, results
were all the same to those found in the overall analysis of the
pooled trials (Table 3).
Safety
Safety analyses were based on AEs found by the clinical and
laboratory examinations in the 12 trials. The treatment-related
AEs (grades $3) and the immunotherapy efficacy for stage IIIA,
IIIB, or IV NSCLC patients are summarized in Tables 4, 5, 6 and
7. Among the 12 trials reviewed, four cytokine and vaccine trials
[20,21,24,30] did not provide detailed data or presented somewhat
contradictory results on safety. Neninger Vinageras et al. [21] and
Wu et al. [30] did not observe serious treatment-related AEs
(grade $3), whereas Butts et al. [22] and Lissoni et al. [16]
reported serious AEs with a significantly less frequently in
immunotherapy groups versus control groups. Because various
AEs occurred in the other eight trials (Table 4), an overall analysis
of safety was conducted. Compared with the control groups, four
kinds of serious AEs occurred more frequently in immunotherapy
groups: diarrhea, hypomagnesemia, leucopenia, and thrombocy-
topenia. Six other kinds of AEs occurred equally in the
immunotherapy and control groups (Tables 5, 6 and 7). The
results indicated that immunotherapy or the combination of
immunotherapy with other therapy could lead to different grades
of AEs or toxic reactions in patients with advanced NSCLC, and
there were fewer episodes of AEs in immunotherapy groups than
in non-immunotherapy groups. Diarrhea, hypomagnesemia, and
leucopenia occurred more frequently in patients receiving cytokine
immunotherapy than in the control group, whereas thrombocy-
topenia occurred more frequently in the mAb subgroup. Patients
receiving vaccine therapy experienced serious AEs with a similar
frequency to the control group. With regard to less serious AEs,
episodes of non-infectious fever were significantly more frequent in
patients receiving immunotherapy than in those receiving
chemotherapy in two trials (P,0.05, P=0.02, respectively)
[16,31].
Discussion
The 12 trials included in this meta-analysis adopted three kinds
of immunotherapy (vaccines, cytokines, mAbs) for advanced
NSCLC patients. Hence the number of published randomized
controlled trials for each kind of immunotherapy would affect the
results of this study. The quality of the reported data influenced
Figure 4. Forest plot of comparison of total effective rate of 10 included studies (Stage IIIA, IIIB, or IV NSCLC). P values are from P-for-
effect modification testing for heterogeneity within or across the groups of regimens. The sizes of data markers are proportional to the number of
total effective rate events in the trials. CI, confidence interval; HR, hazard ratio.
doi:10.1371/journal.pone.0032695.g004
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would be achieved if additional and more comprehensive trials
including all of the efficacy parameters were enrolled. Neverthe-
less, sensitivity analyses on the various efficacy parameters with
alternative exclusions of one of the trials supported the conclusions
drawn from the overall unstratified analyses. Other factors, such as
race differences of patients, curative agents administrated
simultaneously with immunotherapy, different immunotherapy
strategies, different lengths of follow-up, and different proportions
lost to follow-up may confer limitations on this meta-analysis. In
overall studies, no significant publication bias existed [32]. To
avoid bias in the identification and selection of studies, as many
randomized controlled trials as possible were included to improve
the statistical reliability. Our literature search strategy guaranteed
that there was less possibility of important published trials being
overlooked. According to our meta-analysis, all patients with
advanced NSCLC met quality-control specifications and protocol
eligibility [16,21–31]. Subgroup analyses were conducted accord-
ing to recently proposed criteria [33,34], and their validity was
enhanced by the fine discrimination of the subgroups of 12
immunotherapy trials. Finally, Kaplan-Meier estimation of hazard
ratios demonstrated that no statistical inconsistency existed
between the results from each of the original studies and those
of the overall or subgroup analyses of immunotherapy efficacy,
suggesting that the results of this meta-analysis are valid.
Roughly two-thirds of lung cancer patients have locally
advanced or disseminated diseases, and surgery is not adopted
at the time of diagnosis [3]. Therefore, efficient alternative
therapy is needed. The results of the overall meta-analysis
showed that immunotherapy significantly improved the PFS,
total effective rate, and PR rate (P=0.0004, 0.003, 0.002,
respectively) in despite of less influence on the CR rate
(P=0.97), suggesting that immunotherapy may provide advan-
tages for patients with advanced NSCLC. However, immuno-
therapeutic approaches in the treatment of NSCLC were always
applied based on standard treatment modalities or in combina-
tion with multiple immunotherapeutic agents rather than as
single-agent therapy [16,21–31]. Subgroup analyses showed that
only mAb-treated group significantly benefited from immuno-
therapy with regard to PFS, total effective rate, and PR rate
(P=0.0002, 0.0006, 0.001, respectively), with a trend of
improvement in OS (P=0.05). The vaccine-treated group
achieved significant improvement only in OS (P=0.009), and
cytokines-treated group did not significantly improve OS, total
effective rate, PR rate (P=0.08, 0.81, 0.71, respectively).
Furthermore, all three subgroups did not improve the CR rates
(Table 6).
Vaccine and cytokine immunotherapies are novel modalities for
the treatment of advanced NSCLC [21,26,31,35–38], and specific
immune responses have been documented in many advanced
NSCLC studies [9,37]. Our meta-analysis showed, however, that
no significant clinical efficacy was achieved by the two kinds of
immunotherapy when they were applied to advanced NSCLC
patients. In addition, cytokine immunotherapy significantly
Figure 5. Forest plot of comparison of partial response of 8 included studies (Stage IIIA, IIIB, or IV NSCLC). P values are from P-for-effect
modification testing for heterogeneity within or across the groups of regimens. The sizes of data markers are proportional to the number of PR rate
events in the trials. CI, confidence interval; HR, hazard ratio.
doi:10.1371/journal.pone.0032695.g005
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mAb immunotherapy was considered to be the most potential
therapy for advanced NSCLC patients compared with other
immunotherapy strategies.
The importance of AEs and toxicity must be emphasized.
Although mAb immunotherapy could improve efficacy, more AEs
or toxicity occurred in mAb immunotherapy groups than in
control groups, which may discount the efficacy of immunother-
Figure 6. Forest plot of comparison of complete response of 9 included trials (Stage IIIA, IIIB, or IV NSCLC). P values are from P-for-
effect modification testing for heterogeneity within or across the groups of regimens. The sizes of data markers are proportional to the number of CR
rate events in the trials. CI, confidence interval; HR, hazard ratio.
doi:10.1371/journal.pone.0032695.g006
Table 3. Sensitivity analysis for the outcome of studies not using chemotherapy*.
Excluded trials Efficacy items
No. of randomized
controlled trials
subjected to sensitivity
analysis [References]
No. of events/Group
total subjects Odds ratio Heterogeneity test
Experimental Control Mean (95% CI) P-value P-value I
2 (95% CI)
Neninger
Vinageras et al.
a
Overall survival 10 [16,22,24–31] 1215/1479 1276/1474 0.71 (0.58–0.87) 0.001 0.39 6% (0–65%)
Total effective rate 9 [16,22–25,27–30] 424/1306 350/1301 1.33 (1.12–1.58) 0.001 0.52 0% (0–65%)
Complete response 8 [16,22–25,27,28,30] 60/1263 55/1258 1.08 (0.66–1.76) 0.77 0.79 0% (0–75%)
Partial response 7 [16,23–25,27,28,30] 349/1175 283/1175 1.35 (1.13–1.63) 0.001 0.42 1% (0–71%)
Butts et al.
b Overall survival 10 [16,21,24–31] 1189/1431 1245/1431 0.73 (0.59–0.90) 0.004 0.65 0% (0–62%)
Total effective rate 9 [16,21,23–25,27–30] 382/1258 316/1258 1.32 (1.11–1.58) 0.002 0.43 0% (0–65%)
Complete response 8 [16,21,23–25,27,28,30] 11/1215 12/1215 0.92 (0.40–2.10) 0.84 0.61 0% (0–75%)
*Statistical heterogeneity was P.0.1 for all sensitivity analyses. Sensitivity analysis was conducted according to Peto odds ratio method. CI, confidence interval.
aNeninger Vinageras et al. [21] did not report progression-free survival.
bButts et al. [22] did not report progression-free survival and partial response.
doi:10.1371/journal.pone.0032695.t003
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immunotherapy, researchers should develop immunotherapeutic
regimens to reduce or eliminate toxicity and AEs, which can
further improve the quality of life of advanced NSCLC patients. In
fact, aside from individual differences, drug dose, and administra-
tion protocols, the molecular structure of the drug protein [39] is
the most important factor related to efficacy and safety of
immunotherapy.
In the past two decades, 32 mAb drugs have been approved by
U.S. Food and Drug Administration, but two of the three drugs
that could be involved in preclinical trials have been withdrawn
from the market due to their serious adverse events in human
patients [40]. The mAbs can be quickly developed and
demonstrated to be efficacious for advanced NSCLC patients.
However, mAbs immunotherapy-associated AEs and anaphylaxis
could timely occur [23,25,27,29] or be delayed with the treatment
process [41]. To minimize AEs or anaphylaxis, further researches
on two aspects are merited. First, because even mAb containing
less than 10% mouse-derived fragments (i.e., $90% humanized)
can result in AEs [42], fully humanized mAbs should be developed
to eliminate mouse epitopes. Second, the allergenicity of mAbs
should be further attenuated and/or eliminated. The resolution of
these two issues would allow the development of more efficacious
and safer agents for immunotherapy treatment of advanced
NSCLC.
In conclusion, anticancer therapy should be performed based on
an individual assessment of the risk of recurrence and death caused
by the therapy, i.e. the balance between toxicity and efficacy, and
Table 4. Adverse events (grades $3) in advanced NSCLC patients*.
Adverse events
Gatzemeier
et al. [23]
Lasalvia-
Prisco
et al. [24]
Lynch
et al. [25]
O’Brien
et al. [26]
Pirker
et al. [27]
Ridolfi
et al. [28]
Rosell
et al. [29]
Zhong
et al. [31]
Exp Con Exp Con Exp Con Exp Con Exp Con Exp Con Exp Con Exp Con
n=51 n=50 n=44 n=44 n=338 n=338 n=210 n=209 n=557 n=568 n=127 n=114 n=43 n=43 n=14 n=14
A n e m i a 86 N D N D 1 71 57 15 47 69 4N D N D 6646
Leucopenia 17 18 ND ND 138 97 55 49 139 109 22 19 26 20 10 13
Neutropenia 29 29 5 7 198 177 ND ND 289 289 58 45 36 23 ND ND
Thrombocytopenia 18 17 ND ND 33 29 48 34 ND ND 64 36 2 1 ND ND
Nausea ND ND 5 7 18 15 ND ND ND ND 22 23 4 3 ND ND
H y p e r t e n s i o n N D N D 3 4 N DN DN DN DN DN DN DN DN D N D N D N D
Diarrhea ND ND 2 1 17 8 ND ND 25 13 ND ND ND ND ND ND
D y s p n e a N D N D 0 1 N DN DN DN D4 7 5 1 N DN DN D N D N D N D
Neurosensory toxicity ND ND 5 3 ND ND ND ND ND ND ND ND ND ND ND ND
Hypomagnesemia ND ND 1 1 26 2 ND ND ND ND ND ND ND ND ND ND
*No treatment-related adverse events (grade $3) were observed in trials by Neninger Vinageras et al. [21] and Wu et al. [30]; serious adverse events occurred
significantly less frequently in immunotherapy groups than in control groups, but no detailed data were presented in studies by Lissoni et al. [16] and Butts et al. [22].
Note: Exp: experimental group; Con: control group; ND: adverse events (grades $3) were not described.
doi:10.1371/journal.pone.0032695.t004
Table 5. Adverse events (grade $3) in overall immunotherapy and subgroups of advanced NSCLC patients.
Groups Overall immunotherapy [23–29,31]
Cytokines subgroup
[23,25,27,29] Vaccines subgroup [26] mAbs subgroup [24,28,31]
Adverse events OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI
P-
value
Anemia 1.00 0.80–1.25 0.9787 0.88 0.67–1.16 0.3659 1.47 0.96–2.23 0.0752 0.61 0.17–2.20 0.4522
Diarrhea 2.03 1.21–3.40 0.0074 2.07 1.21–3.51 0.0075 / / / 1.87 0.17–20.80 0.6110
Dyspnea 0.90 0.60–1.34 0.5987 0.93 0.62–1.39 0.72 / / / 0.31 0.01–7.62 0.4720
Hypertension 0.75 0.17–3.34 0.7032 / / / / / / 0.69 0.15–3.14 0.6335
Hypomagnesemia 9.13 2.76–30.17 0.0003 13.46 3.19–56.86 0.0004 / / / 0.93 0.06–14.97 0.9588
Leucopenia 1.35 1.14–1.60 0.0005 1.48 1.22–1.80 0.0001 1.16 0.74–1.81 0.5155 0.92 0.53–1.57 0.7477
Nausea 1.02 0.68–1.53 0.9292 1.24 0.66–2.33 0.5030 / / / 0.81 0.46–1.43 0.4635
Neurosensory toxicity 1.66 0.40–6.98 0.4861 / / / / / / 1.56 0.37–6.65 0.5441
Neutropenia 1.14 0.98–1.32 0.0962 1.17 0.98–1.40 0.0765 / / / 1.19 0.76–1.86 0.4403
Thrombocytopenia 1.46 1.14–1.88 0.0029 1.15 0.77–1.72 0.5049 1.53 0.94–2.49 0.0904 2.00 1.24–3.22 0.0044
Note: mAbs, monoclonal antibodies; OR, odds ratio. CI, confidence interval. No treatment-related adverse events (grade $3) were observed in trials by Neninger
Vinageras et al. [21] and Wu et al. [30]; serious adverse events occurred but significantly less frequently in immunotherapy groups than in control groups and no
detailed data were presented in studies by Lissoni et al. [16] and Butts et al. [22].
doi:10.1371/journal.pone.0032695.t005
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e32695Table 6. Adverse events (grade $3) in overall immunotherapy and subgroups of advanced NSCLC patients.
Overall immunotherapy [23–29,31] Experimental (N=1384) Control (N=1380) Odds ratio 95% CI P-value
Anemia 182 181 1.0030 0.80–1.25 0.9787
Diarrhea 44 22 2.0269 1.21–3.40 0.0074
Dyspnea 47 52 0.8978 0.60–1.34 0.5987
Hypertension 3 4 0.7473 0.17–3.34 0.7032
Hypomagnesemia 27 3 9.1326 2.76–30.17 0.0003
Leucopenia 407 325 1.3523 1.14–1.60 0.0005
Nausea 49 48 1.0185 0.68–1.53 0.9292
Neurosensory toxicity 5 3 1.6642 0.40–6.98 0.4861
Neutropenia 615 570 1.1365 0.98–1.32 0.0962
Thrombocytopenia 165 117 1.4612 1.14–1.88 0.0029
Adverse event items in cytokines subgroup [23,25,27,29] Experimental (N=989) Control (N=999) Odds ratio 95% CI P-value
Anemia 107 121 0.88 0.67–1.16 0.3659
Diarrhea 42 21 2.07 1.21–3.51 0.0075
Dyspnea 47 51 0.93 0.62–1.39 0.72
Hypertension ND ND / / /
Hypomagnesemia 26 2 13.46 3.19–56.86 0.0004
Leucopenia 320 244 1.48 1.22–1.80 0.0001
Nausea 22 18 1.24 0.66–2.33 0.5030
Neurosensory toxicity ND ND / / /
Neutropenia 552 518 1.17 0.98–1.40 0.0765
Thrombocytopenia 53 47 1.15 0.77–1.72 0.5049
Adverse event items in vaccines subgroup [26] Experimental (N=210) Control (N=209) Odds ratio 95% CI P-value
Anemia 71 54 1.47 0.96–2.23 0.0752
Diarrhea ND ND / / /
Dyspnea ND ND / / /
Hypertension ND ND / / /
Hypomagnesemia ND ND / / /
Leucopenia 55 49 1.16 0.74–1.81 0.5155
Nausea ND ND / / /
Neurosensory toxicity ND ND / / /
Neutropenia ND ND / / /
Thrombocytopenia 48 34 1.53 0.94–2.49 0.0904
Adverse event items in mAbs subgroup [24,28,31] Experimental (N=185) Control (N=172) Odds ratio 95% CI P-value
Anemia 4 6 0.61 0.17–2.20 0.4522
Diarrhea 2 1 1.87 0.17–20.80 0.6110
Dyspnea 0 1 0.31 0.01–7.62 0.4720
Hypertension 3 4 0.69 0.15–3.14 0.6335
Hypomagnesemia 1 1 0.93 0.06–14.97 0.9588
Leucopenia 32 32 0.92 0.53–1.57 0.7477
Nausea 27 30 0.81 0.46–1.43 0.4635
Neurosensory toxicity 5 3 1.56 0.37–6.65 0.5441
Neutropenia 63 52 1.19 0.76–1.86 0.4403
Thrombocytopenia 64 36 2.00 1.24–3.22 0.0044
Note: No treatment-related adverse events (grade $3) were observed in trials by Neninger Vinageras et al. [21] and Wu et al. [30]; serious adverse events occurred but
significantly less frequently in immunotherapy groups versus control groups and no details were provided by Lissoni et al. [16] and Butts et al. [22]. mAbs, monoclonal
antibodies; CI, confidence interval. ND: the corresponding adverse events (grades $3) were not described.
doi:10.1371/journal.pone.0032695.t006
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therapies must be assessed appropriately for physicians to decide
how to select the optimal treatment strategy. We found that
immunotherapy using mAbs, rather than cytokines and vaccines,
could significantly improved PFS, total effective rate, and PR rate,
suggesting that mAb immunotherapy may become a standard
complementary therapeutic approach for advanced NSCLC
patients in the future. In despite of this, more efficacious and
safer (i.e., causing fewer AEs and less allergenicity) immunother-
apeutic agents should also be developed.
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